title: American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
authors.affiliation: Division of Gastroenterology, Washington University School of Medicine, Saint Louis, Missouri.
authors.forename: Themistocles
authors.initials: T
authors.lastname: Dassopoulos
authors.forename: Shahnaz
authors.initials: S
authors.lastname: Sultan
authors.forename: Yngve T
authors.initials: YT
authors.lastname: Falck-Ytter
authors.forename: John M
authors.initials: JM
authors.lastname: Inadomi
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005762:Gastroenterology; D006801:Humans; D015122:Mercaptopurine / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use*; D012074:Remission Induction; D012955:Societies, Medical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States
chemical_list: D014409:Tumor Necrosis Factor-alpha; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
keywords: 6-MP; 6-mercaptopurine; ACG; ADA; AZA; American College of Gastroenterology; BSG; British Society of Gastroenterology; CD; CDAI; CI; CZP; Crohn's Disease Activity Index; Crohn's disease; ECCO; European Crohn's and Colitis Organisation; GRADE; Grading of Recommendations Assessment, Development and Evaluation; HR; IBD; IFX; MTX; OR; PICO; RCT; RR; SIR; TNF; adalimumab; azathioprine; certolizumab pegol; confidence interval; hazard ratio; inflammatory bowel disease; infliximab; methotrexate; odds ratio; population, intervention, comparator, and outcome; randomized controlled trial; relative risk; standardized incidence ratio; tumor necrosis factor